Lobbying registration dated 2026-04-02
Registrant: Iain Graham
Client: Novo Nordisk Canada Inc.
Targeted institutions:
Privy Council Office (PCO)
Employment and Social Development Canada (ESDC)
Intergovernmental Affairs Secretariat (IGA)
Health Canada (HC)
Indigenous Services Canada (ISC)
National Research Council (NRC)
Canadian Institutes of Health Research (CIHR)
Global Affairs Canada (GAC)
House of Commons
Prime Minister's Office (PMO)
Canadian Heritage (PCH)
Treasury Board Of Canada Secretariat (TBS)
Senate of Canada
Canada Foundation for Innovation
Agriculture and Agri-Food Canada (AAFC)
Parks Canada (PC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Canadian Human Rights Tribunal (CHRT)
Finance Canada (FIN)
Innovation, Science and Economic Development Canada (ISED)
Legislative bills: S-201
C-64
Acts: Pharmacare Act
Government funding received:
Lobbying activity details:
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Advocate for the establishment of public-private partnerships to support chronic disease prevention.
Advocate for the implementation of a federal diabetes and obesity strategy.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.